Kane Biotech launches new branding for StrixNB oral health products for dogs and cats

Posted in: Press Releases

WINNIPEG, Manitoba – October 19, 2016 – Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) is pleased to announce the launch of new packaging and branding for StrixNBTM.

StrixNB is a premium line of oral health products designed to fight plaque and tartar. Available exclusively in veterinary clinics, it was brought to market in 2014 and has quickly gained a reputation as being safe and effective amongst both veterinarians and pet owners. It’s patent-pending technology works against dental associated bacteria by breaking through dental biofilm, leaving bacteria exposed for eradication.

“Kane Biotech is excited to bring to market a current, updated look to our premium line of StrixNB oral health products”, says Mark Ahrens-Townsend, President and CEO. “We know we have an exceptional product – third party studies have repeatedly demonstrated its efficacy and safety. The new look solidifies our place at the top of the oral health market for companion pets.”

The new StrixNB packaging was launched this week at the CanWest Veterinary Conference in Banff, Alberta. “It’s already received positive feedback from vets who’ve had a chance to review it,” says Grant Humphrey, VP Sales, “and vets appreciate that we’ve achieved the LRVHP seal of approval from Health Canada.”

Periodontal disease is the number one disease in dogs and cats, creating a pet oral care market in the United States that in 2015 was estimated at $775 million and is growing at 33% annually.

press-release

For more information about StrixNB please contact Grant Humphrey, VP Sales at ghumphrey@kanebiotech.com.  As well please visit the new StrixNB website at www.strixNB.com

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, antimicrobials, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to numerous human and animal health related problems such as wound care infections, recurrent urinary tract infections, tooth decay, medical device associated and hospital-acquired infections, and foodborne bacterial infections. According to the United States National Institutes of Health biofilms are estimated to be responsible for 80% of all human bacterial infections and cost individuals, industry, governments and hospitals billions of dollars each year.  As such, there is significant interest in safe and effective products that can combat the biofilm problem.

Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. The Corporation has evidence that these technologies have the potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.

Kane Biotech has a portfolio of biotechnologies, intellectual property (patents, patents pending and trademarks) and products developed by the Corporation’s own biofilm research expertise and acquired from leading research institutions.    StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™, coactiv+™ and Kane® are trademarks of Kane Biotech Inc.   The Corporation is listed on the TSX Venture Exchange under the symbol “KNE”.

For more information, please contact:

Mark Ahrens-Townsend

President & CEO

Kane Biotech Inc.
204-477-7592 phone
204-474-7552 fax

ir@kanebiotech.com

www.kanebiotech.com